The trial is funded by NINDS. His support is funding for salary substitution to devote 30% of his effort to the trial) None None None None None None Thanh N. Nguyen Boston Medical Center Medtronic (PI Clear Study)* None None None None None None Peter M. Pollak Mayo Clinic None None None None None None None Pasquale Santangeli Hospital of the University of Pennsylvania None None Abbott Medical*; Biosense Webster*; Biotronik*; Medtronic* None None Abbott Medi- cal*; Baylis Medical*; Biosense Webster* None Anjail Z. Sharrief University of Texas Medical School at Houston None Omron (donation of blood pressure machines for clinical care and research)* None None None None None Sidney C. Smith Jr University of North Carolina None None None None None None None Tanya N. Turan (AAN WG Representa- tive) Medical Univer- sity of South Carolina Sanofi-Regeneron (alirocumab is donated to the CREST2, for which she is the director of medical management) None None None None Boehringer Ingelheim*; Gore*; Pfizer None Linda S. Wil- liams Roudebush VA Medical Center VHA (VA HSR&D PI) None None None None None None This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be significant if (a) the person receives $5000 or more during any 12-month period, or 5% or more of the person s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $5000 or more of the fair market value of the entity. A relationship is considered to be modest if it is less than significant under the preceding definition. *Modest. Significant. Appendix 1. 